Fresenius SE & Co. KGaA · XETR:FRE

Fresenius SE & Co. KGaA — Shareholder Meeting (August 2020)

35 slides from Fresenius SE & Co. KGaA's shareholder meeting presentation, Aug 28, 2020

  1. Slide 1: Annual General Meeting – Fresenius SE & Co. KGaA

    Annual General Meeting – Fresenius SE & Co. KGaA August 28, 2020 Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA

  2. Slide 2: Welcome!

    Welcome! Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 2

  3. Slide 3: In battle against the coronavirus

    In battle against the coronavirus Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 3

  4. Slide 4: Acute care hospitals: a focal point

    Acute care hospitals: a focal point Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 4

  5. Slide 5: Ensuring dialysis continues during the pandemic

    Ensuring dialysis continues during the pandemic Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 5

  6. Slide 6: Maintaining the production and distribution of life-sustaining products

    Maintaining the production and distribution of life-sustaining products Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 6

  7. Slide 7: A consistent shift to Mobile Work

    A consistent shift to Mobile Work Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 7

  8. Slide 8: Accelerating digitalization across the board

    Accelerating digitalization across the board Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 8

  9. Slide 9: Putting even more “we” in Fresenius

    Putting even more “we” in Fresenius Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 9

  10. Slide 10: Solid business development despite the pandemic

    Solid business development despite the pandemic Sales EBIT Net income in €m +5% -1% -6% 18,055 2,248 2,248 17,256 928 875 H1/2019 H1/2020 H1/2019 H1/2020 H1/2019 H1/2020 Constant currency growth rates; EBIT and net income before special items Annual General Meeting | August 28, 2020 | © Fresenius SE

  11. Slide 11: Pandemic puts pressure on share price

    Pandemic puts pressure on share price 55 50 45 40 35 30 25 Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 11

  12. Slide 12: Learning the right lessons

    Learning the right lessons Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 12

  13. Slide 13: Solidarity, not selfishness

    Solidarity, not selfishness Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 13

  14. Slide 14: 2019: A year of investment

    2019: A year of investment Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 14

  15. Slide 15: 16th consecutive record year

    16th consecutive record year Sales (in €bn) Net income (in €m) 35.5 1,915 1,872 32.8 33.0 1,804 29.5 28.0 1,560 1,436 23.5 20.5 1,088 19.5 1,028 944 16.0 16.5 14.2 758 12.4 657 10.8 11.4 496 7.3 7.9 422 437 7.1 330 222 166 115 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 201

  16. Slide 16: 27th consecutive dividend increase proposed

    27th consecutive dividend increase proposed 0.84 0.80 0.75 15% 0.62 CAGR 0.55 0.44 0.42 € 0.37 0.32 0.29 0.25 0.23 0.22 0.19 0.02 1993 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2019: Proposal Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 16

  17. Slide 17: Expanding and advancing home dialysis

    Expanding and advancing home dialysis Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 17

  18. Slide 18: New dialysis machine for emerging markets

    New dialysis machine for emerging markets Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 18

  19. Slide 19: First biosimilar launched

    First biosimilar launched Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 19

  20. Slide 20: Investments in production facilities

    Investments in production facilities Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 20

  21. Slide 21: Challenges in Germany

    Challenges in Germany Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 21

  22. Slide 22: New business models

    New business models Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 22

  23. Slide 23: Digitalization in the hospitals

    Digitalization in the hospitals Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 23

  24. Slide 24: Acquisition of Malteser hospitals in Germany

    Acquisition of Malteser hospitals in Germany Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 24

  25. Slide 25: Acquisition of hospital in Albacete, Spain

    Acquisition of hospital in Albacete, Spain Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 25

  26. Slide 26: New proton beam therapy center in Madrid

    New proton beam therapy center in Madrid Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 26

  27. Slide 27: Additional acquisitions in Colombia

    Additional acquisitions in Colombia Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 27

  28. Slide 28: Leading provider of post-acute care

    Leading provider of post-acute care Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 28

  29. Slide 29: Milestone in project business

    Milestone in project business Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 29

  30. Slide 30: Superbly positioned for continued growth

    Superbly positioned for continued growth Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 30

  31. Slide 31: 2020 guidance revised to include COVID-19 effects

    2020 guidance revised to include COVID-19 effects +3 to +6% Sales growth constant currency -4 to +1% Net income growth constant currency Before special items, incl. estimated Covid-19-effects Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 31

  32. Slide 32: Medium-term goals for 2020-2023 confirmed

    Medium-term goals for 2020-2023 confirmed +4 to +7% Average annual sales growth organic +5 to +9% Average annual earnings growth organic plus ~1% small to mid-size acquisitions Before special items Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 32

  33. Slide 33: Anchoring sustainability even more firmly in Fresenius

    Anchoring sustainability even more firmly in Fresenius Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 33

  34. Slide 34: Our commitment: Ever better medicine for ever more people

    Our commitment: Ever better medicine for ever more people Annual General Meeting | August 28, 2020 | © Fresenius SE & Co. KGaA 34

  35. Slide 35: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive

Fresenius SE & Co. KGaA — Shareholder Meeting (August 2020) on 6ix